Insomnia - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Insomnia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Insomnia - Pipeline Review, H1 2015', provides an overview of the Insomnia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Insomnia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Insomnia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Insomnia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Insomnia Overview 9
Therapeutics Development 10
Pipeline Products for Insomnia - Overview 10
Pipeline Products for Insomnia - Comparative Analysis 11
Insomnia - Therapeutics under Development by Companies 12
Insomnia - Therapeutics under Investigation by Universities/Institutes 14
Insomnia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Insomnia - Products under Development by Companies 18
Insomnia - Products under Investigation by Universities/Institutes 20
Insomnia - Companies Involved in Therapeutics Development 21
Actelion Ltd 21
Alexza Pharmaceuticals, Inc. 22
Eisai Co., Ltd. 23
Evotec AG 24
Grupo Ferrer Internacional, S.A. 25
Heptares Therapeutics Ltd. 26
Intec Pharma ltd. 27
Intra-Cellular Therapies, Inc. 28
Johnson & Johnson 29
Merck & Co., Inc. 30
Minerva Neurosciences, Inc. 31
Neurim Pharmaceuticals Ltd 32
Novartis AG 33
Reviva Pharmaceuticals Inc. 34
Rottapharm SpA 35
Shionogi & Co., Ltd. 36
Somnus Therapeutics, Inc. 37
Takeda Pharmaceutical Company Limited 38
Insomnia - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 47
ACT-462206 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CR-5542 Series - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
EVT-201 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ITI-007 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
JNJ-42847922 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LASSBio-785 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LASSBio-786 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
lemborexant - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lorediplon - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MIN-202 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MK-8133 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
piromelatine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ramelteon - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
RP-15000 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
S-117957 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
UCM-765 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
zaleplon - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
zaleplon DR - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
zaleplon GR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
zolpidem tartrate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Insomnia - Recent Pipeline Updates 73
Insomnia - Dormant Projects 80
Insomnia - Discontinued Products 83
Insomnia - Product Development Milestones 85
Featured News & Press Releases 85
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 85
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 86
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 87
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 87
Feb 09, 2012: Ferrer Announces Positive Results From Phase I Clinical Trials Of Lorediplon In Insomnia 88
Dec 14, 2011: McGill University Health Centre Researchers Discover Potential Insomnia Drug 89
Oct 07, 2011: Takeda Discontinues Development Of Ramelteon In Europe For Treatment Of Insomnia 90
Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11 90
Jun 15, 2011: Somnus's Phase II Study Of SKP-1041 For Sleep Maintenance Insomnia Shows Significant Reduction Of Mid-Night Awakenings without Next-Day Cognitive Impairment 91
Jun 01, 2011: Somnus Therapeutics Completes Successful Phase II Study Of SKP-1041 For Sleep Maintenance Insomnia 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94

List of Tables

Number of Products under Development for Insomnia, H1 2015 10
Number of Products under Development for Insomnia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Insomnia - Pipeline by Actelion Ltd, H1 2015 21
Insomnia - Pipeline by Alexza Pharmaceuticals, Inc., H1 2015 22
Insomnia - Pipeline by Eisai Co., Ltd., H1 2015 23
Insomnia - Pipeline by Evotec AG, H1 2015 24
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 25
Insomnia - Pipeline by Heptares Therapeutics Ltd., H1 2015 26
Insomnia - Pipeline by Intec Pharma ltd., H1 2015 27
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 28
Insomnia - Pipeline by Johnson & Johnson, H1 2015 29
Insomnia - Pipeline by Merck & Co., Inc., H1 2015 30
Insomnia - Pipeline by Minerva Neurosciences, Inc., H1 2015 31
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2015 32
Insomnia - Pipeline by Novartis AG, H1 2015 33
Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 34
Insomnia - Pipeline by Rottapharm SpA, H1 2015 35
Insomnia - Pipeline by Shionogi & Co., Ltd., H1 2015 36
Insomnia - Pipeline by Somnus Therapeutics, Inc., H1 2015 37
Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 46
Insomnia Therapeutics - Recent Pipeline Updates, H1 2015 73
Insomnia - Dormant Projects, H1 2015 80
Insomnia - Dormant Projects (Contd..1), H1 2015 81
Insomnia - Dormant Projects (Contd..2), H1 2015 82
Insomnia - Discontinued Products, H1 2015 83
Insomnia - Discontinued Products (Contd..1), H1 2015 84